Revisiting [PtCl2(cis-1,4-DACH)]: An underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7182-7192

  Margiotta, Nicola ^a   Marzano, Cristina ^b   Gandin, Valentina ^b   Osella, Domenico ^c   Ravera, Mauro ^c   Gabano, Elisabetta ^c   Platts, James A ^d   Petruzzella, Emanuele ^a   Hoeschele, James D ^e   Natile, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e EASTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA POLYMERASE; DOUBLE STRANDED DNA; LIGAND; OXALIPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE; RNA POLYMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSENSOR; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; CROSS LINKING; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; ISOMER; LIPOPHILICITY; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; QUANTUM MECHANICS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; DNA; DNA ADDUCTS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; ORGANOPLATINUM COMPOUNDS; QUANTUM THEORY;

EID: 84866889209     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3006838     Document Type: Article

References (65)

1. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; Verlag Helvetica Chimica Acta: Zurich, Switzerland, 2000; 563 pp.
2. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumour metal compounds: more than theme and variations. Dalton Trans. 2008, 183-194.
3. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573-584.
4. Reedijk, J. Platinum anticancer coordination compounds: study of DNA binding inspires new drug design. Eur. J. Inorg. Chem. 2009, 1303-1312.
5. Wong, E.; Giandomenico, C. M. Current status of platinum- based antitumor drugs. Chem. Rev. 1999, 99, 2451-2466.
6. Hall, M. D.; Mellor, H. R.; Callaghan, R.; Hambley, T. W. Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem. 2007, 50, 3403-3411.
7. Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113-8127.
8. Hoeschele, J. D.; Hollis Showalter, H. D.; Kraker, A. J.; Elliott, W. L.; Roberts, B. J.; Kampf, J. W. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1, 4-diaminocyclohexane ligand in a unique locked boat conformation. J. Med. Chem. 1994, 37, 2630-2636.
9. Shamsuddin, S.; Takahashi, I.; Siddik, Z. H.; Khokhar, A. R. Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1, 4-diaminocyclohexane as nonleaving amine group. J. Inorg. Biochem. 1996, 61, 291-301.
10. 2]. J. Inorg. Biochem. 1998, 71, 29-35.
11. Ali, M. S.; Khokhar, A. R. cis-1, 4-Diaminocyclohexane-Pt(II) and -(IV) adducts with DNA bases and nucleosides. J. Inorg. Biochem. 2003, 96, 452-456.
12. Shamsuddin, S.; Ali, M. S.; Whitmire, K. H.; Khokhar, A. R. Synthesis characterization and X-ray crystal structures of cis-1, 4-diaminocyclohexane- platinum(II) nucleobase adducts. Polyhedron 2007, 26, 637-644.
13. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 2005, 4, 307-320.
14. Fuertes, M. A.; Alonso, C.; Perez, J. M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 2003, 103, 645-662.
15. Ranaldo, R.; Margiotta, N.; Intini, F. P.; Pacifico, C.; Natile, G. Conformer distribution in (cis-1, 4-DACH)bis(guanosine-5′-phosphate) platinum(II) adducts: a reliable model for DNA adducts of antitumoral cisplatin. Inorg. Chem. 2008, 47, 2820-2830.
16. Natile, G.; Marzilli, L. G. Non-covalent interactions in adducts of platinum drugs with nucleobases in nucleotides and DNA as revealed by using chiral substrates. Coord. Chem. Rev. 2006, 250, 1315-1331 and references therein.
17. Kasparkova, J.; Suchankova, T.; Halamikova, A.; Zerzankova, L.; Vrana, O.; Margiotta, N.; Natile, G.; Brabec, V. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt(II) chelate complex incorporating the cis-1, 4-diaminocyclohexane carrier ligand. Biochem. Pharmacol. 2010, 79, 552-564.
18. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.-L.; Van Laethem, J.-L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R. G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25, 1658-1664.
19. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J., Sr; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
20. Sobrero, A. F.; Maurel, J.; Fehrenbacher, L.; Scheithauer, W.; Abubakr, Y. A.; Lutz, M. P.; Vega-Villegas, M. E.; Eng, C.; Steinhauer, E. U.; Prausova, J.; Lenz, H.-J.; Borg, C.; Middleton, G.; Kroning, H.; Luppi, G.; Kisker, O.; Zubel, A.; Langer, C.; Kopit, J.; Burris, H. A., III. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyr-imidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 2311-2319.
21. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987, 34, 155-166.
22. Woynarowski, J. M.; Chapman, W. G.; Napier, C.; Herzig, M. C. S.; Juniewicz, P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998, 54, 770-777.
23. Zhou, Y.; Ling, X. L.; Li, S. W.; Li, X. Q.; Yan, B. Establishment of a human hepatoma multidrug resistant cell line in vitro. World J. Gastroenterol. 2010, 16, 2291-2297.
24. Kamazawa, S.; Kigawa, J.; Kanamori, Y.; Itamochi, H.; Sato, S.; Iba, T.; Terakawa, N. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 2002, 86, 171-176.
25. Zhang, Y. H.; Wu, Q.; Xiao, X. Y.; Li, D. W.; Wang, X. P. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett. 2010, 291, 76-82.
26. Noordhuis, P.; Laan, A. C.; van de Born, K.; Losekoot, N.; Kathmann, I.; Peters, G. J. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem. Pharmacol. 2008, 76, 53-61.
27. Gatti, L.; Perego, P. Cellular resistance to oxaliplatin and drug accumulation defects. In Cancer Drug Discovery and Development: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy; Bonetti, A., Leone, R., Muggia, F., Howell, S. B., Eds.; Humana Press: New York, 2009; pp 115-124.
28. Wersinger, C.; Rebel, G.; Lelong-Rebel, I. H. Detailed study of the different taurine uptake systems of colon LoVo MDR and non-MDR cell lines. Amino Acids 2000, 19, 667-685.
29. Abramkin, S. A.; Jungwirth, U.; Valiahdi, S. M.; Dworak, C.; Habala, L.; Meelich, K.; Berger, W.; Jakupec, M. A.; Hartinger, C. G.; Nazarov, A. A.; Galanski, M.; Keppler, B. K. {(1R, 2R, 4R)-4-Methyl-1, 2-cyclohexanediamine} oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. J. Med. Chem. 2010, 53, 7356-7364.
30. Platts, J. A.; Hibbs, D. E.; Hambley, T. W.; Hall, M. D. Calculation of the hydrophobicity of platinum drugs. J. Med. Chem. 2001, 44, 472-474.
31. Ghezzi, A. R.; Aceto, M.; Cassino, C.; Gabano, E.; Osella, D. Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J. Inorg. Biochem. 2004, 98, 73-78.
32. Liu, X.; Testa, B.; Fahr, A. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 2011, 28, 962-977.
33. Platts, J. A.; Oldfield, S. P.; Reif, M. M.; Palmucci, A.; Gabano, E.; Osella, D. The RP-HPLC measurement and QSPR analysis of logPo/w values of several Pt(II) complexes. J. Inorg. Biochem. 2006, 100, 1199-1207.
34. Bagni, G.; Osella, D.; Sturchio, E.; Mascini, M. Deoxyribonucleic acid (DNA) biosensors for environmental risk assessment and drug studies. Anal. Chim. Acta 2006, 573-574, 81-89.
35. Ravera, M.; Bagni, G.; Mascini, M.; Dabrowiak, J. C.; Osella, D. The activation of platinum(II) antiproliferative drugs in carbonate medium evaluated by means of a DNA-biosensor. J. Inorg. Biochem. 2007, 101, 1023-1027.
36. 4(DSMO)(Im)] (NAMI-A) with the proteins and the weak interaction with nucleobases. J. Inorg. Biochem. 2004, 98, 984-990.
37. Bagni, G.; Ravera, M.; Osella, D.; Mascini, M. Electrochemical biosensors as a screening tool of in vitro DNA-drug interaction. Curr. Pharm. Anal. 2005, 1, 217-224.
38. Mascini, M.; Bagni, G.; Di Pietro, M. L.; Ravera, M.; Baracco, S.; Osella, D. Electrochemical biosensor evaluation of the interaction between DNA and metallo-drugs. BioMetals 2006, 19, 409-418.
39. Ravera, M.; Bagni, G.; Mascini, M.; Osella, D. DNA- metallodrugs interactions signaled by electrochemical biosensors: an overview. Bioinorg. Chem. Appl. 2007, No. 91078.
40. Geary, W. J. The use of conductivity measurements in organic solvents for the characterisation of coordination compounds. Coord. Chem. Rev. 1971, 7, 81-122.
41. Wilkins, R. G. Kinetics and Mechanism of Reactions of Transition Metal Complexes, 2nd ed.; Wiley-VCH: Weinheim, Germany, 2002; Chapter 3.10.3.
42. Wu, Y.; Pradhan, P.; Havener, J.; Boysen, G.; Swenberg, J. A.; Campbell, S. L.; Chaney, S. G. NMR solution structure of an oxaliplatin 1, 2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J. Mol. Biol. 2004, 341, 1251-1269.
43. Spingler, B.; Whittington, D. A.; Lippard, S. J. 2.4 Å crystal structure of an oxaliplatin 1, 2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg. Chem. 2001, 40, 5596-5602.
44. Mutter, S. T.; Platts, J. A. Unpublished results.
45. Brabec, V.; Malina, J.; Margiotta, N.; Natile, G.; Kasparkova, J. Unpublished results.
46. 2]. Indian J. Chem. 1970, 8, 193-194.
47. Kidani, Y.; Inagaki, K. Antitumor activity of 1, 2-diaminocyclo-hexane- platinum complexes against sarcoma-180 ascites form. J. Med. Chem. 1978, 21, 1315-1318.
48. Gandin, V.; Pellei, M.; Tisato, F.; Porchia, M.; Santini, C.; Marzano, C. A novel copper complex induces paraptosis in colon cancer cells via the activation of ER stress signalling. J. Cell. Mol. Med. 2012, 16, 142-151.
49. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
50. Heudi, O.; Mercier-Jobard, S.; Cailleux, A.; Allain, P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin. Biopharm. Drug Dispos. 1999, 20, 107-116.
51. Valko, K.; Snyder, L. R.; Glajch, J. L. Retention in reversed- phase liquid-chromatography as a function of mobile-phase composition. J. Chromatogr., A 1993, 656, 501-520.
52. Vreven, T.; Byun, K. S.; Komaromi, I.; Dapprich, S.; Montgomery, J. A., Jr.; Morokuma, K.; Frisch, M. J. Combining quantum mechanics methods with molecular mechanics methods in ONIOM. J. Chem. Theory Comput. 2006, 2, 815-826.
53. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
54. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A. Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. GAUSSIAN 03, revision E.01; Gaussian, Inc.: Wallingford, CT, 2004.
55. Becke, A. D. A new mixing of Hartree-Fock and local density-functional theories. J. Chem. Phys. 1993, 98, 1372-1377.
56. Waller, M. P.; Robertazzi, A.; Platts, J. A.; Hibbs, D. E.; Williams, P. A. Hybrid density functional π-stacking interactions: application to benzenes, pyridines, and theory for DNA bases. J. Comput. Chem. 2006, 27, 491-504.
57. Singh, U. C.; Kollman, P. A. An approach to computing electrostatic charges for molecules. J. Comput. Chem. 1984, 5, 129-145.
58. Grimme, S. Semiempirical GGA-type density functional constructed with a long-range dispersion correction. J. Comput. Chem. 2006, 27, 1787-1799.
59. Ahlrichs, R.; Bar, M.; Haser, M.; Horn, H.; Kolmel, C. Electronic structure calculations on workstation computers: the program system turbomole. Chem. Phys. Lett. 1989, 162, 165-169.
60. Stewart, J. J. P. Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. J. Mol. Model. 2007, 13, 1173-1213.
61. Korth, M.; Pitonak, M.; Rezac, J.; Hobza, P. A transferable H-bonding correction for semiempirical quantum-chemical methods. J. Chem. Theory Comput. 2010, 6, 344-352.
62. Stewart, J. J. P. MOPAC, 2009. http://openMOPAC.net (Accessed February 2, 2012).
63. Gkionis, K.; Platts, J. A. QM/MM investigation into binding of square-planar platinum complexes to DNA fragments. J. Biol. Inorg. Chem. 2009, 14, 1165-1174.
64. Klamt, A.; Schuurmann, G. COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc., Perkin Trans. 1993, 2, 799-805.
65. Lu, X.-J.; Olson, W. K. 3DNA: a software package for the analysis, rebuilding and visualization of three-dimensional nucleic acid structures. Nucleic Acids Res. 2003, 31, 5108-5121.